Proteomics International - Biosimilars, Biomarkers & Therapeutics

proteomics.com.au

Founded 2001 Listed on ASX April 2015 - Proteomics International Laboratories Ltd (PILL, ASX: PIQ) Proteomics International is a medical technology company focused on proteomics – the industrial-scale study of the structure and function of proteins. Proteomics International has over 16 years of experience in providing specialist analytical services on a fee-for-service basis . The strength of the company’s research expertise in finding new diagnostic protein biomarkers has also resulted in a ground-breaking predictive test for diabetic kidney disease – PromarkerD.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

PORTAL INNOVATIONS EXPANDS CHICAGO OPERATIONS TRIPLES SPACE IN FULTON LABS

Portal Innovations | February 03, 2022

news image

Portal Innovations continues its momentum in Chicago by launching the second phase of its operations with the opening of 35,000 square feet of premier wet and dry lab and office space at 400 North Aberdeen in Fulton Labs. The new facility will allow Portal, a life sciences venture development engine, to grow and scale its investment in early-stage biotech companies in Chicago. Portal has tapped Patrick Flavin to serve as President of its flagship Chicago operation. With over 20 ye...

Read More

MEDICAL

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

news image

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More

MEDICAL

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

news image

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More

CELL AND GENE THERAPY

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

news image

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More
news image

INDUSTRIAL IMPACT

PORTAL INNOVATIONS EXPANDS CHICAGO OPERATIONS TRIPLES SPACE IN FULTON LABS

Portal Innovations | February 03, 2022

Portal Innovations continues its momentum in Chicago by launching the second phase of its operations with the opening of 35,000 square feet of premier wet and dry lab and office space at 400 North Aberdeen in Fulton Labs. The new facility will allow Portal, a life sciences venture development engine, to grow and scale its investment in early-stage biotech companies in Chicago. Portal has tapped Patrick Flavin to serve as President of its flagship Chicago operation. With over 20 ye...

Read More
news image

MEDICAL

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More
news image

MEDICAL

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More
news image

CELL AND GENE THERAPY

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More